Drug Profile
NT 501
Alternative Names: Ciliary neurotrophic factor - Neurotech; Ciliary neurotrophic factor implant - Neurotech; CNTF implant - Neurotech; Encapsulated CNTF - Neurotech; NT-501; Retinitis pigmentosa encapsulated cell therapy - Neurotech; RexenusLatest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Neurotech USA
- Developer National Eye Institute; Neurotech USA; Stanford University; University of Miami
- Class Cell therapies; Eye disorder therapies; Gene therapies
- Mechanism of Action Ciliary neurotrophic factor replacements; Neurogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Retinal telangiectasis
- Phase II/III Retinitis pigmentosa
- Phase II Glaucoma; Usher syndromes
- Phase I/II Colour vision defects
- No development reported Dry macular degeneration; Optic nerve disorders
Most Recent Events
- 22 Feb 2023 Phase III development for Retinal telangiectasis is ongoing in Australia, France, United Kingdom, USA and Germany (Intraocular, Implant)
- 03 Nov 2022 Pooled efficacy and adverse events data from a phase III Protocol A and Protocol B trial Retinal (macular) telangiectasis released by Neurotech Pharmaceuticals
- 23 Sep 2022 Neurotech Pharmaceuticals completes phase III trial in Retinal telangiectasia (In adults, In the elderly) in Australia, Germany and USA (Intraocular, Implant) (NCT03319849)